Stability of gadolinium chelates and their biological consequences: New data and some comments

British Journal of Radiology

Volumn 81, Issue 963, 2008, Pages 258-259

  Port, M ^a   Idee, J M ^a   Medina, C ^a   Dencausse, A ^a   Corot, C ^a  

^a Laboratoire Guerbet   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM CHELATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; CONTRAST MEDIUM; GADOBUTROL; GADOLINIUM 1,4,7,10-TETRAAZACYCLODODECANE-N,N',N'',N'''-TETRAACETATE; GADOLINIUM PENTETATE; HETEROCYCLIC COMPOUND; ORGANOMETALLIC COMPOUND; UNCLASSIFIED DRUG;

CLINICAL PROTOCOL; DISSOCIATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STABILITY; DRUG TISSUE LEVEL; HEMODYNAMICS; HUMAN; LETTER; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PH; PHYSICAL CHEMISTRY; PREDICTION; TEMPERATURE; TISSUE DISTRIBUTION; ANIMAL; HALF LIFE TIME; MOUSE; NOTE;

ANIMALS; CONTRAST MEDIA; DRUG STABILITY; GADOLINIUM DTPA; HALF-LIFE; HETEROCYCLIC COMPOUNDS; MICE; ORGANOMETALLIC COMPOUNDS;

EID: 40749143638     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/94141681     Document Type: Letter

References (15)

1. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol 2007;80:581-2.
2. Tweedle MF. Stability of gadolinium chelates. Br J Radiol 2007;80:583-4.
3. Morcos SK. Reply to Schmitt-Willich and Tweedle MF. Br J Radiol 2007;80:584-5.
4. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Brit J Radiol 2007;80:73-6.
5. Idée JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging : a review. Fundam Clin Pharmacol 2006;20:563-76.
6. Kumar K. Macrocyclic polyamino carboxylate complexes of Gd(III) as magnetic resonance imaging contrast agents. J Alloys Comp 1997;249:163-72.
7. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999;99:2293-352.
8. Tweedle MF. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992;27(Suppl1):S2-6.
9. Kumar K, Tweedle MF. Macrocyclic polyaminocarboxylate complexes of lanthanides as magnetic resonance imaging contrast agents. Pure and Appl Chem 1993;65:515-20.
10. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 1992;10:641-8.
11. Pulukkody KP, Norman TJ, Parker D, Royle L, Broan CJ. Synthesis of charged and uncharged complexes of gadolinium and yttrium with cyclic polyazaphosphinic acid ligands for in vivo applications. J Chem Soc Perkin Trans 1993;2:605-20.
12. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2007;2:200-2.
13. Kanal E, Barkovich AJ, Bell C, Borgstede JP, Bradley WG Jr, Froelich JW, et al. ACR guidance document for safe MR practice: 2007. Am J Roentgenol 2007;188:1-27.
14. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate and gadodiamide in mice and rats. Invest Radiol 1995;30:372-80.
15. Harrison A, Walker CA, Pereira KA, Parker D, Royle L, Pulukkody K, et al. Hepato-biliary and renal excretion in mice of charged and neutral gadolinium complexes of cyclic tetra-aza-phosphinic and carboxylic acids. Magn Reson Imaging 1993;11:761-70.